18 day average time to death once infected. 2200 cases 18 days ago. 67 deaths today. 3%. Trending up since mid June.

The pandemic is almost over..... Herd immunity by end of summer w/ death rates plunging. LMAO where do you come up with this shit?

Assume Musk’s death rate. Assume a low population % to achieve herd by end of summer.

Either way, we’re looking at a shit-ton of deaths per day to achieve herd by end of summer.

Note: a shit-ton is equivalent to 24 metric assloads.

We shall see.

https://www.google.com/amp/s/api.nationalgeographic.com/distribution/public/amp/science/2020/07/coronavirus-deadlier-than-many-believed-infection-fatality-rate-cvd

happy 4th C. Be green!

Gap #1 filled. Gap #2 on deck.

Poof... $BBillions gone, that fast.

screw the gap

Zzzzzzz. Mr. Volume needs a swift kick in the ass from Mr. News.

LoL. Couldn’t resist.

They’d just wait a day and it would drop back down to 30 cents

https://www.google.com/amp/s/www.forbes.com/sites/emilyprice/2020/06/27/researchers-are-looking-at-cannabis-as-a-potential-way-to-prevent-covid-19/amp/

No one. He was naked!

Beep Beep. It’s the lung tests all over again! LMAO!

There’s no mistake in disinformation.

LMAO. Reading this thread tells me all hell’s breaking loose. Definitely a buy signal.

Beep beep. It’s the lung tests all over again LMAO.

Learned from the best . Paws crossed.

Eye on the 100!

Puff puff give, puff puff give, you’re f’ing up the rotation yo.

Hydrozycloroquine with Z Max.... lmao.

You must be smokin some good shit!

Beep beep!

Good call! Patiently waiting.

BTW, just saw the rally monkey run by beating Wile E. Coyote over the head with a frying pan.

Has to be a bullish sign!

Thoughts on tomorrow’s open?

Wise. Follow the volume.

I am certain the .285 gap will fill.

Thanks again! 5th time is a charm

Hi C. Love the chart format! Hope all is well. Be green!
Hound.

Gap fills at .158. Show me the $$!

A big pharma partner would go a LONG way at this point.

The gap always closes. Missed the last 2 and won’t be missing this one.!

$IPIX Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic

The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses.

The ongoing Brilacidin anti-SARS-CoV-2 research being conducted at the RBL is separate from the ongoing research being performed at a Public Health Research Institute (PHRI). The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication.

For researchers and institutions interested in collaborating on Brilacidin for COVID-19, please send inquiries to: mailto://covid19@ipharminc.com

Brilacidin and COVID-19
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing an established safety and efficacy database on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Ongoing laboratory testing conducted at a U.S. Regional Biocontainment Laboratory (RBL), and at a Public Health Research Institute (PHRI), supports Brilacidin’s antiviral ability to safely inhibit SARS-CoV-2 in both animal and human cell lines. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. These data collectively support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—anti-COVID-19 therapeutic candidate.

Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/

About Innovation Pharmaceuticals:

Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at http://www.IPharmInc.com.

Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

The testing of Brilacidin was conducted by researchers at one of the U.S. Regional Biocontainment Laboratories (RBLs). Few compounds have shown activity against SARS-CoV-2, as summarized in the article linked below.

Andersen P, et al. “Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents.” Int J Infect Dis. 2020 Feb 17;93:268-276. doi: 10.1016/j.ijid.2020.02.018.

https://www.sciencedirect.com/science/article/pii/S120197122030076X
https://ars.els-cdn.com/content/image/1-s2.0-S120197122030076X-gr5.jpg

VERO cells, a monkey kidney cell line commonly used to screen small molecule inhibitors of viruses, were used to test whether Brilacidin inhibits SARS-CoV-2. Cells were pretreated with Brilacidin at increasing concentrations (at 2 µM and at 10 µM) for two hours prior to the infection. Cells treated with the vehicle alone (Dimethyl sulfoxide or DMSO) were maintained alongside, as controls. At 16 hours post-infection (16hpi), researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the Brilacidin treated cells as compared to the vehicle-alone control, as shown below. (The higher number of asterisks denote higher statistical significance compared to control.)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/908f63ab-a42b-4045-9874-267371bb8e6b

The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.

In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications. Additional data, based on successfully completed Phase 2 clinical studies in other clinical indications, using various modes of administration, show Brilacidin’s ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines, identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19.

Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line

Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2 Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving data from a leading Public Health Research Institute (PHRI) showing Brilacidin inhibits SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human cell line. Brilacidin, in comparison to vehicle control, exhibited an inhibitory effect on SARS-CoV-2 in a dose-dependent manner—an average 29 percent inhibition at 0.1ug/ml (the lowest concentration) to an 85 percent inhibition at 100ug/ml (the highest concentration).

The Brilacidin anti-SARS-CoV-2 research being conducted at the PHRI is separate from research being performed at a U.S. Regional Biocontainment Laboratory (RBL), both with BSL-3 testing capabilities.

“This human cell line data is highly significant, with exciting implications,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells. Across the coming weeks, we anticipate sharing additional anti-SARS-CoV-2 data from both research institutions as we work towards initiating a clinical study of Brilacidin for the treatment of COVID-19.”

For the experiment, the SARS-CoV-2 spike pseudotyped luciferase virus was incubated with Brilacidin at different concentrations—from a low of 0.1ug/ml to a high of 100ug/ml—for 1 hour before being added to HEK/293T cells (a human kidney cell line) expressing hACE2 for 2 hours. Then, the infected cells were cultured in media for 3 days before cells were lysed, with the inhibitory effect measured as a function of luciferase activity. Multiple measurements were taken to determine an average efficacy.

The primary investigator characterized the results as promising, especially given inhibitory effects in this particular human cell line are difficult to achieve based on the PHRI’s experience testing other defensins. The researcher also theorizes Brilacidin’s inhibitory effect may be partially due to the drug’s ability to prevent viral entry by blocking the SARS-CoV-2 Spike 1 (S1) Receptor-Binding Domain (RBD) from interacting with the Angiotensin-Converting Enzyme-2 (ACE2) receptor, the method by which the novel coronavirus gains entry into human cells. Additional anti-SARS-CoV-2 testing in human cell lines is underway at both the PHRI and the RBL to further elucidate Brilacidin’s antiviral properties.

Related, the article below highlights how defensins/peptides and their synthetic mimics, like Brilacidin, might be able to block the uptake of the novel coronavirus into host cells via the ACE2 receptor given their unique molecular properties. The article further points out that SARS-CoV-2 might be losing the battle in the intestines, in contrast to the lungs, due to defensins (present naturally) exerting a protective effect.

“Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.” CS Med. Chem. Lett. 2020. Published online May 18, 2020.

https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00233 (pdf)
For researchers and institutions interested in collaborating on Brilacidin for COVID-19, please send inquiries to: covid19@ipharminc.com

Read the full press release here:

http://www.globenewswire.com/news-release/2020/05/26/2038595/0/en/Innovation-Pharmaceuticals-Receives-Data-from-Public-Health-Research-Institute-Showing-Brilacidin-Inhibits-SARS-CoV-2-COVID-19-in-a-Human-Cell-Line.html

$IPIX in the NEWS - http://ipharminc.com/press-release

$IPIX COVID News Filed w/ SEC -

https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

$IPIX Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

April 1 - The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.

——————-

https://www.eurekalert.org/pub_releases/2020-06/gmu-nsa060520.php

June 5 - Aarthi Narayanan, Associate Professor, National Center for Biodefense and Infectious Diseases, received $35,000 from Innovation Pharmaceuticals, Inc., for a project in which she is examining the use of Brilacidin for the treatment of coronavirus infections.

No doubt about it.

Ya. I’ll get right on that.

The phrase has been used w & w/o a hyphen for years.

You got that right. Mako & Wile E. Coyote Et Alia from planet Propaganda.

$IPIX Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

April 1st - The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.

——————-

https://www.eurekalert.org/pub_releases/2020-06/gmu-nsa060520.php

June 5 - Aarthi Narayanan, Associate Professor, National Center for Biodefense and Infectious Diseases, received $35,000 from Innovation Pharmaceuticals, Inc., for a project in which she is examining the use of Brilacidin for the treatment of coronavirus infections.